A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

Sponsor
Bristol-Myers Squibb
Study ID
NCT07171983
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • BMS-986454 — DRUG
    Specified dose on specified days
  • Placebo — OTHER
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid Arthritis

Key Dates

First listed
Sep 15, 2025
Start date
Feb 27, 2026
Status verified
Jul 2026
Primary completion
Jun 28, 2027
Completion
Aug 25, 2027

Study Design

Enrollment
46 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: Administration of BMS-986454
  • Placebo Comparator: Part A: Placebo
  • Experimental: Part B: Administration of BMS-986454
  • Placebo Comparator: Part B: Placebo

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 6 months ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Find similar trials

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies